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Elefteriades Aortic Symposium 2010Indications for aortic replacementJohn A. Elefteriades, MDThis monograph reviews currently accepted criteria for extirpation of the aneurysmal thoracic aorta. Presence of symptoms
suffices to justify resection regardless of size. For asymptomatic patients, resection of the ascending aorta at 5 to 5.5 cm is
warranted. The descending aorta can be watched until slightly larger sizes (ie, 5.5–6 cm). Marfan disease or bicuspid aortic
valve encourages resection in the smaller region of these size ranges. A nomogram permits adjustment of intervention cri-
teria for extremes of body size. A recently computerized aortic risk calculator automatically applies exponential equations
for determination of yearly risk of rupture or dissection for individual patients (available at: http://aorta.yale.edu). Evolving
modalities to enhance decision making include positron emission tomography imaging of aneurysm metabolic activity,
measurement of mechanical properties of the aorta by echocardiography, and assessment of the biomolecular state of the
aneurysm with the ‘‘RNA Signature’’ test. (J Thorac Cardiovasc Surg 2010;140:S5-9)During the past 12 years, we have performed epidemiologic
investigations predicated on the information in the Database
of the Aortic Institute at Yale-New Haven aimed at articu-
lating evidence-based criteria for intervention for extirpa-
tion of the aneurysmal thoracic aorta. Such criteria are
important because thoracic aortic aneurysm is a largely
asymptomatic disease—with the first symptom often being
death or a severely life-threatening complication such as
rupture or dissection. This article reviews our findings and
takes a look into the future to seewhat enhancements of cur-
rent intervention criteria may be on the horizon.HOW FAST DOES THE AORTA GROW?
It is important first and foremost to note that the aneu-
rysmal thoracic aorta grows slowly, on the order of 1
mm per year (Figure 1). The descending aorta grows
a bit faster (3 mm/y) than the ascending aorta (1 mm/
y).1 Reports of more rapid growth are usually erroneous,
resulting from measurement of non-corresponding portions
of the aorta or, especially, across non-vertical portions of
the aorta (eg, the aortic arch). The complexity of taking
and comparing measurements of thoracic aortic size, and
sources of error, are discussed fully in a recent publica-
tion.2 The one setting where bona fide rapid growth can
be seen is that in which there has been an asymptomatic
intercurrent aortic dissection between images; in such a sit-
uation, as we see in our laboratory models of aortic dissec-
tion,3 there is usually an immediate increase in aortic
diameter. These situations, however, are rare. Suffice toFIGURE 1. Thoracic aortic aneurysm, although virulent, is an indolent
disease. The aorta grows slowly (1 cm per decade), as indicated in this
schematic. The descending aorta generally grows faster than the ascending
aorta.
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The Journal of Thoracic and Casay, although thoracic aortic dissection is a virulent dis-
ease, it is an indolent one. This can be seen also in the sur-
vival curves presented in Figure 2, which show that most
patients live for years after diagnosis of thoracic aortic an-
eurysm, and only patients with large aneurysms have any
substantial 5-year mortality.rdiovascular Surgery c Volume 140, Number 6S S5
FIGURE 2. Five-year hazard estimates are illustrated for patients as
a function of initial aneurysm size (P<.0045).
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OR DISSECT?
We have looked at the issue of size at the time of rupture
or dissection in 2 ways.
We have looked at the time of rupture or dissection on
a lifetime basis. This results in the graphs shown in
Figure 3. It can be seen in those figures that there are sharp
hinge points for both the ascending and the descending
aorta. By the time in a patient’s life when the ascending
aorta reaches 6 cm in diameter, the patient has incurred
a 34% risk of rupture or dissection. The descending aorta,
for reasons that are not understood, does not rupture or dis-
sect until approximately 1 cm or larger diameter. This is
counterintuitive, because the descending aorta has fewer la-
mellae than the ascending aorta, consistent with its normal
smaller size.
We have also looked at the likelihood of rupture or dis-
section on a yearly basis. This required extremely robust
data, with many hard end points at different sizes. This anal-
ysis shows that risk of rupture, dissection, and death
increases in a roughly stepwise fashion as the aorta grows
(Figure 4). Rupture and dissection reach approximately
4% yearly by an aortic size of 6 cm. Death reaches 10%FIGURE 3. Lifetime increase in risk of rupture or dissection as the aorta enlar
cending aorta (A) and 7 cm for the descending aorta (B).
S6 The Journal of Thoracic and Cardiovascular Surgeyearly by this dimension (many, but not all deaths due to
the aorta). The combined end point of rupture, dissection,
or death reaches 14.1% by an aortic dimension of 6 cm.AT WHAT SIZE SHOULD THE THORACIC AORTA
BE REPLACED?
These data permit evidence-based criteria for interven-
tion.4 Because rupture and dissection occur at 6 cm, most
adverse events can be prevented by operating at a criterion
less than 6 cm. We recommend a criterion of 5.5 cm for the
ascending aorta for most patients. For patients with Marfan
disease, bicuspid aortic valve, or a family history of aortic
dissection, we decrease the criterion to 5 cm. For the de-
scending aorta, because adverse events occur at larger sizes,
slightly larger criteria can be applied. These criteria are
shown in Figure 5.
It is well known from our data and those of other centers5
that dissection can and does occasionally occur in small aor-
tas. However, one must keep in mind, assuming that aortic
dimension follows a bell curve, that the pool of individuals
with mildly dilated aortas must be huge (in the millions,
likely). So, if one considers the numerator of patients
presenting with dissection at small sizes over the huge
denominator of patients with small aneurysms, the ratio
(or likelihood of an aortic event) is very low. Thus, it is
not recommended that operation be carried out for minor
aortic dilatation.5
We recently tested our algorithm for aortic decision
making based on symptoms and size of the aorta in the
real-world setting.2 We prospectively applied our criteria
(surgery for symptoms or for size 5.5 ascending or 5.0 in pa-
tients with Marfan syndrome or bicuspid aortic valve) to
121 patients followed longitudinally long-term. No patient
triaged to medical management died of aortic rupture, con-
firming the safety of medical management barring symp-
toms or large aortic size. Of the patients triaged to surgery
who did not undergo operation for a variety of reasons,
more than 50% died, confirming that the algorithm doesges to specific dimensions. Note the abrupt hinge-point at 6 cm for the as-
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FIGURE 4. Research has shown that the likelihood of rupture, dissection,
or death increases sharply for aneurysms that reach 6 cm or more. (The
rates indicated for ‘‘Rupture or Dissection’’ and for ‘‘Rupture, Dissection,
or Death’’ are lower than the sum of the rates in individual categories
because patients with multiple complications were counted only once in
the combined categories.) On the basis of this information, investigators
have determined that many patients with aneurysms in the ascending aorta
require surgery when the artery reaches 5.5 cm.
Elefteriades Aortic Symposium 2010indeed identify patients at risk of aortic events. This real-
world testing of the algorithm lends credence to an
approach based on symptoms and size.
Another important factor is patient size. It is hard for a sin-
gle size criterion to apply for patients of highly disparate body
size, especially very small or very large patients. Recently,
we have published a nomogram that permits prediction of
a precise aortic risk based on body size and aneurysm size;
the patient’s body surface area is entered on one axis, and
the aortic size on the other; the nomogram then reads the
yearly risk of rupture or dissection for that specific patient.6
This is similar in principle to Svensson and colleagues’7 cri-
terion of aortic cross-sectional area to body height (recom-
mended intervention criterion is ratio > 10). We have
recently provided on our website (http://www.aorta.yale.
edu) an Aortic Risk Calculator that automates this process;
a patient or physician enters patient height, patient weight,
and maximum aortic size; the yearly risk of rupture orFIGURE 5. Intervention recommendations that incorporate size criteria devel
aneurysm.
The Journal of Thoracic and Cadissection is then calculated automatically by computerized
exponential equations1 and displayed in the window.
Of course, the decision to intervene depends not only on
the size of the aorta and the risk of natural complications but
also on the risk of the surgical procedure. For elective sur-
gery especially, which is the appropriate reference point
for prophylactic aortic replacement, current levels of surgi-
cal risk are exceptionally low—approaching those of
routine coronary artery bypass graft surgery.8NON-SIZE–RELATED INTERVENTION CRITERIA
Size criteria have proved valuable over the years in guid-
ing aortic surgery, but they are certainly imperfect. Certain
time-honored non-size intervention criteria are important
clinically. We hope also that novel additional modalities
to inform the decision making beyond size can come to clin-
ical fruition. Criteria in addition to size are summarized in
Table 1. Above the line are shown accepted criteria, and
below the line are shown evolving criteria being evaluated
on a research basis.
Symptoms
It must be emphasized that a symptomatic thoracic aortic
aneurysm must be resected regardless of size. Pain (sub-
sternal for ascending aneurysms and interscapular for de-
scending aneurysms) is an accepted harbinger of rupture
or dissection and must be taken seriously. We recently pub-
lished the case of a young woman who underwent opera-
tion for symptoms despite a small aneurysm and
remarkably benign aortic images.9 At surgery, she was
found to have a small aortic dissection, too subtle to be
picked up on imaging, but severe enough to cause pain;
without resection, this patient would likely have gone on
to frank, longitudinally extensive aortic dissection. Many
patients have been harmed by not being resected despite
symptoms because the aortic dimensions did not satisfy
a particular size criterion. The size criteria are only for
asymptomatic patients.oped as an integral component for managing patients with thoracic aortic
rdiovascular Surgery c Volume 140, Number 6S S7
TABLE 1. Non-size indications for aortic replacement
Symptoms
Family history of early dissection
PET scan
Mechanical properties
Biomarkers
PET, Positron emission tomography.
Aortic Symposium 2010 ElefteriadesFamily History of Early Dissection
Aortic events follow definite family patterns. These pat-
terns are beginning to be associated with specific genetic
mutations.10-15 In such situations, we often advise early
preemptive extirpation of the aneurysm aorta, even at
sizes in the 4.5 to 5.0 cm range.
Positron Emission Tomography Scan
There is evolving evidence that positron emission tomog-
raphy scan can detect high-grade abnormal metabolic activ-
ity in an aneurysm. This may correlate with malignant
behavior,16,17 and such imaging may become a valid
criterion for intervention in the future.
Mechanical Properties
We have previously analyzed the mechanical properties
of the ascending aorta by epi-aortic echocardiography in
the operating room in patients undergoing aortic surgery
(and in normal controls undergoing coronary artery bypass
surgery).18 These data show a precise dovetailing of clinical
and engineering data. Specifically, the hinge point for clin-
ical events occurs at 6 cm. It is at this same dimension, 6 cm,
that the engineering characteristics of the aorta deteriorate
markedly. At this dimension, the aorta loses its elasticity
(Figure 6) and becomes a rigid tube; at this dimension
and beyond, the force of systolic contraction can no longer
be dissipated in expanding the aorta, and this force all be-
comes wall tension. We hope to transition these engineering
measurements to transesophageal or even transthoracic
echocardiography. Once we are able to do so, we hope to ar-
ticulate specific criteria for elastic modulus or wall tension
that may enhance surgical decision making.FIGURE 6. Distensibility values in normal aortas and aortic aneurysms of
different diameters. Distensibility of ascending aortic aneurysms decreases
rapidly as diameter increases, to very low values at dimensions greater than
6 cm.
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Avariety of biomarkers are being applied to aortic aneu-
rysms, predicated on the evolving understanding of the
pathophysiologic mechanisms underlying aneurysm
formation.19 D-dimer is 100% sensitive (but not specific)
for aortic dissection, but D-dimer detects the dissection
after it occurs. We need biomarkers that can predict rupture
or dissection, based on biology, before they occur. Matrix
metalloproteinases (MMPs) hold some progress; recent
work in our laboratory (Donald Botta, MD, unpublished
data, 2007) has shown that aortic tissue levels of MMPs
are accurately reflected in the serum, raising the possibility
of following aneurysms by serum MMP levels. Recent ad-
ditional work in our laboratory20 has identified a panel of
41 RNAs (screened from 33,000 tested) (called the ‘‘RNA
Signature’’ of thoracic aortic aneurysm) that can discrimi-
nate accurately from the peripheral blood whether a patient
harbors an aneurysm. We are carrying out our final confir-
matory validation in another group of patients, with the
hope that this RNA panel can serve as a screening test for
thoracic aortic aneurysm disease in family members or
even in the general population. Furthermore, because these
RNAs are intimately involved in pathophysiologic mecha-
nisms of aneurysm disease (inflammation, apoptosis, prote-
olysis), it is possible that following RNA levels over time
will give us a snapshot into the molecular biology of a par-
ticular aneurysm in a particular patient. These snapshots
may help us predict which aneurysms are about to rupture
or dissect.CONCLUSIONS
In the future, it is likely that traditional criteria such as
symptoms and size will be supplemented by currently in-
vestigational criteria, including positron emission tomogra-
phy scan, mechanical properties, and RNA profiles or other
gene-based parameters. We hope that these evolving testing
modalities will inform our decision making beyond current
capabilities.References
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